Here are five things to know:
1. Dr. Ando is global pharmaceutical company Novo Nordisk’s former board chairman. Dr. Ando also previously served as Cell Tech Group’s CEO.
2. With more than 35 years of global drug development and general management experience, Dr. Ando is an EW Healthcare Partners’ senior advisor.
3. As executive vice president and deputy CEO for Pharmacia AB, Dr. Ando led research and development while holding responsibilities for manufacturing, IT, business development and mergers and acquisitions. He served as Pharmacia and Pharmacia & Upjohn’s research and development head for nine years, overseeing the FDA approval process for 17 drugs.
4. Dr. Ando held several senior clinical positions at Pfizer early in his career. He served as the Astra Research Centre’s president and held several senior appointments at GlaxoSmithKline.
5. Dr. Ando received his medical degree from Linköping, Sweden-based Linköping University.
“Dr. Ando’s extensive experience across the many facets of the global pharmaceutical industry will undoubtedly be valuable as we transition into a commercial ophthalmic company with our planned U.S. launches of Dexycu and, if approved, Yutiq,” said EyePoint Board Chairman David Mazzo, PhD.
More articles on supply chain:
Eyepoint expects to secure $25.5M to support 2 product launches — 5 insights
EyePoint Pharmaceuticals reports 338k increase in third-quarter revenue — 6 takeaways
EyePoint Pharmaceuticals to share Phase 3 study results on drug pending FDA approval — 3 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.